Laboratorios Sanfer

Privately held: no public share price · Mexico

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
GLP-1 receptorPeptide
ObesityType 2 Diabetes

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
November 2027 (1)
efpeglenatidePhase 3Type 2 Diabetes
Est. primary completion 2027-11 · NCT07379333 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.